Drug Trial Radar · NCT05392946
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
49
Actual
Start
Aug 11, 2022
Primary completion
Sep 18, 2026
Study completion Sep 29, 2028
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial studies the side effects and best dose of iberdomide and how well it works in combination with daratumumab, bortezomib, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving iberdomide in combination with daratumumab, bortezomib, and dexamethasone may kill more cancer cells in patients with newly diagnosed multiple myeloma.
Conditions
- Plasma Cell Myeloma
Interventions
BortezomibDrug
Given SC
DaratumumabBiological
Given SC
DexamethasoneDrug
Given PO
IberdomideDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) of iberdomide (Phase I)Time frame: Up to 12 cycles. Each cycle is 28 days.
- Complete response rate (Phase II)Time frame: Up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Rochester
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.